# Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/combination-therapy-of-pembrolizumab-plus-axitinib-for-a-patient-on-hemodialysis/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yuki Katsumata,Yoshihide Kawasaki,Kayu Tanaka,Daisuke Nakayama,Hiromichi Katayama,Shuichi Shimada,Yohei Satake,Takuma Sato,Naoki Kawamorita,Shinichi Yamashita,Testuya Sato,Kosuke Shoji,Koji Mitsuzuka,Akihiro Ito |
| Citations | 6 |
| DOI | 10.1159/000519855 |
| Fields | Economics, Econometrics and Finance,Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://karger.com/cro/article-pdf/14/3/1522/3748376/000519855.pdf |
| OpenAlex ID | https://openalex.org/W3217680622 |
| PMID | 34899246 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Kayu Tanaka](https://scholariq.org/researchers/kayu-tanaka/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.